XLRN Acceleron Pharma Inc.

26.80
+0.26  (0.98%)
Previous Close 26.54
Open 26.51
Price To book 4.36
Market Cap 1.01B
Shares 37,746,000
Volume 217,871
Short Ratio 6.51
Av. Daily Volume 417,210

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 updated data at ASH 2016.
Luspatercept
Low or intermediate-risk MDS patients who are erythropoiesis-stimulating agent (ESA) naïve or ring sideroblast negative (RS-)
Phase 3 enrollment to be completed 2H 2017.
Luspatercept - MEDALIST
Myelodysplastic syndromes (MDS) cancer
Phase 3 enrollment to be completed 2H 2017.
Luspatercept - BELIEVE
b -thalassemia
Phase 2 dosing initiation announced December 22, 2016. Open label initial data due late 2017, with randomized part of trial to be initiated in 2018.
ACE-083
Facioscapulohumeral muscular dystrophy
Phase 2 preliminary data due 2H 2017.
Dalantercept - DART Study
Renal Cell Carcinoma (RCC) - cancer

Latest News

  1. Acceleron to Participate in Two Healthcare Investor Conferences in February
  2. ACCELERON PHARMA INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  3. Top Insider Buys Highlight for Week of Jan. 6
  4. Acceleron Outlines Corporate Goals and Priorities for 2017
  5. Acceleron Outlines Corporate Goals and Priorities for 2017
  6. Former CEO of Finish Line Inc. (FINL) Sells Shares as Underperformance Persists; Other Notable Insider Transactions
  7. Acceleron to Webcast Presentation at 35th Annual J.P. Morgan Healthcare Conference
  8. Acceleron Announces First Patient Treated in Phase 2 Trial of ACE-083 in Facioscapulohumeral Muscular Dystrophy
  9. Acceleron Announces First Patient Treated in Phase 2 Trial of ACE-083 in Facioscapulohumeral Muscular Dystrophy
  10. Coverage initiated on Acceleron Pharma by Oppenheimer
  11. ACCELERON PHARMA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  12. Acceleron and Celgene Announce Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia Presented at the 58th Annual Meeting of the American Society of Hematology
  13. Celgene, Acceleron Launch Blood Disorder Study (CELG)
  14. Acceleron, Celgene Present Myelodysplastic Syndromes Data
  15. Acceleron and Celgene Announce Preliminary Results from an Investigator Initiated Phase 2 Study of Sotatercept in Myelofibrosis at the 58th Annual Meeting of the American Society of Hematology
  16. Acceleron, Celgene Seek to Replace Entrenched Anti-Anemia Drugs in MDS Treatment
  17. Acceleron and Celgene Announce Updated Results from Ongoing Phase 2 Studies of Luspatercept in Myelodysplastic Syndromes at the 58th Annual Meeting of the American Society of Hematology
  18. ETFs with exposure to Acceleron Pharma, Inc. : December 2, 2016
  19. Acceleron Pharma to Host Conference Call and Webcast to Review Data Presented at the 58th American Society of Hematology Annual Meeting and Exposition
  20. Acceleron Pharma, Inc. breached its 50 day moving average in a Bearish Manner : XLRN-US : December 1, 2016